Log in

Company updateBusinessLine

Biocon gets European Commission nod for breast cancer biosimilar

Positive+402 sources

GreyOak summary

Biocon received European Commission approval for Pebrilzo, a biosimilar version of pertuzumab, to treat HER2-positive breast cancer. This marks the fifth oncology biosimilar approved by the company in both Europe and the US. The drug is indicated for neoadjuvant and adjuvant treatment of adults with high-risk early breast cancer.

What it affects

  • BioconBIOCONPositive +40

    Received EU approval for breast cancer biosimilar.Rolling sentiment Positive +23

Source

Read the original at BusinessLine

More Biocon news

All Biocon news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy